Nutraveris
Tuesday, April 2, 2019
Category : NEWS, REGULATORY | Author : experts | Comment : No Comments
Tags:

NOL, Nutraveris Online, the most efficient data solution to create, keep up-to-date and launch your products in the 28 EU member states, used for 10years by more than 500 industry leaders informs you:

 

The European Council (Article 50) agreed on Thursday 21 March to extend the UK’s departure date to 22 May 2019, provided the Withdrawal Agreement is approved by the House of Commons (UK) by 29 March 2019 at the latest.

However the withdrawal agreement was rejected a third time last Friday by the House of Commons (UK) by 344 votes against 286.

The United Kingdom must now indicate to the European Council before 12 April 2019 a way forward. European Council President Donald Tusk called a special European Council on 10 April.

A UK exit from the EU with “no deal” on 12 April 2019 is now a likely scenario. In that case, the United Kingdom will become a third country and Union law will cease to apply in the United Kingdom. There will be no transition period.

Brexit: third negative UK vote on the withdrawal agreement

Since December 2017, the European Commission has been preparing for a “no-deal” scenario.

For more information:

 

This information has been sourced by NOL, a collaborative and complete tool which contains all Regulatory, Scientific and Marketing data

  • It solves all regulatory issues since it contains the required information on all ingredients authorized in the 28 European member states…on regulatory status, health claims, authority opinions
  • It protects your investments since it is updated in real time with reliable quality information analyzed and reviewed by our experts, available hotline.
  • It enables you to be the most responsive with monthly reports and live alerts and a personal use of the information with a report editing tool and customizable bookmarks.

With NOL let’s : 

  • Formulate new innovative products
  • Check if your already existing formulas are still compliant with the in force regulations
  • Adapt your existing formulas to the requirements of other European countries where you are willing to export them
  • Do scientific & regulatory & marketing monitoring which enable to anticipate the withdrawal of products, the safety issues, new interesting scientific studies, the arrival of new players on the market…

 

More information on www.nutraveris.com

Contact our Scientific & Regulatory experts at NUTRAVERIS

contact@nutraveris.com, +33 2 96 76 54 87

Thursday, March 28, 2019
Category : NEWS, INGREDIENTS, INNOVATION, CLINICAL EVIDENCE | Author : experts | Comment : No Comments
Tags:

NOL, Nutraveris Online, the most efficient data solution to create, keep up-to-date and launch your products in the 28 EU member states, used for 10years by more than 500 industry leaders informs you:

 

This randomized, controlled, in vivo study evaluated the effect of 50 mg/kg/d of lutein supplementation during 14 days, on ethanol-induced memory deficits in the object recognition task in adult Wistar rats.

Rats were exposed to ethanol (3 g/kg/d), during 7 days, after 8 days of lutein supplementation.

Ethanol administration induced a memory deficit and increased acetylcholinesterase activity, however, it did not alter the parameters of oxidative stress, evaluated in the cortex and hippocampus. Oral administration of lutein attenuated memory deficit (Figure) and the increase of acetylcholinesterase activity induced by ethanol.

ethanol-induced memory deficits

Effect of administration of lutein (50 mg/kg), ethanol (3g/kg), and the co-administration of ethanol and lutein on the discrimination index in the object recognition task. Data are mean ± SEM, for n = 10-11 animals in each group. * Indicates a significant difference (p < 0.05) compared to the control group (Olive oil/Saline).

 

These results provide evidence that lutein is an alternative treatment for ethanol-induced memory deficit, and suggest the involvement of cholinergic system.

 

Geiss JMT, Sagae S, Paz EDR, de Freitas ML, Souto NS4, Furian AF, Oliveira MS3, Guerra GP. Oral administration of lutein attenuates ethanol-induced memory deficit in rats by restoration of cholinergic function. Physiol Behav. 2019 Feb 14. pii: S0031-9384(18)31017-5.

 

This information has been sourced by NOL, a collaborative and complete tool which contains all Regulatory, Scientific and Marketing data

  • It solves all regulatory issues since it contains the required information on all ingredients authorized in the 28 European member states…on regulatory status, health claims, authority opinions
  • It protects your investments since it is updated in real time with reliable quality information analyzed and reviewed by our experts, available hotline.
  • It enables you to be the most responsive with monthly reports and live alerts and a personal use of the information with a report editing tool and customizable bookmarks.

With NOL let’s : 

  • Formulate new innovative products
  • Check if your already existing formulas are still compliant with the in force regulations
  • Adapt your existing formulas to the requirements of other European countries where you are willing to export them
  • Do scientific & regulatory & marketing monitoring which enable to anticipate the withdrawal of products, the safety issues, new interesting scientific studies, the arrival of new players on the market…

 

More information on www.nutraveris.com

Contact our Scientific & Regulatory experts at NUTRAVERIS

contact@nutraveris.com, +33 2 96 76 54 87

Tuesday, March 26, 2019
Category : NEWS, REGULATORY | Author : experts | Comment : No Comments
Tags:

NOL, Nutraveris Online, the most efficient data solution to create, keep up-to-date and launch your products in the 28 EU member states, used for 10years by more than 500 industry leaders informs you:

 

Following a request by Prime Minister Theresa May, the European Council (Article 50) agreed on Thursday 21 March to extend the UK’s departure date to 22 May 2019, provided the Withdrawal Agreement is approved by the House of Commons (UK) by 29 March 2019 at the latest.

In that scenario, most of the legal effects of Brexit will apply as of 1 January 2021, i.e. after a transition period of 21 months, the terms of which are set out in the draft Withdrawal Agreement.

Brexit

However, if the Withdrawal Agreement is not approved by the House of Commons this week, the European Council has agreed to an extension until 12 April 2019. In that scenario, the United Kingdom would be expected to indicate a way forward before this date.

While the European Union continues to hope that it will not be the case, this means that if the Withdrawal Agreement is not ratified by Friday 29 March, a “no-deal” scenario may occur on 12 April 2019.  In a “no-deal” scenario, the UK will become a third country without any transitionary arrangements. All EU law will cease to apply to the UK from that moment onwards. There will be no transition period, as provided for in the Withdrawal Agreement.

 

Since December 2017, the European Commission has been preparing for a “no-deal” scenario.

For more information:

 

This information has been sourced by NOL, a collaborative and complete tool which contains all Regulatory, Scientific and Marketing data

  • It solves all regulatory issues since it contains the required information on all ingredients authorized in the 28 European member states…on regulatory status, health claims, authority opinions
  • It protects your investments since it is updated in real time with reliable quality information analyzed and reviewed by our experts, available hotline.
  • It enables you to be the most responsive with monthly reports and live alerts and a personal use of the information with a report editing tool and customizable bookmarks.

With NOL let’s : 

  • Formulate new innovative products
  • Check if your already existing formulas are still compliant with the in force regulations
  • Adapt your existing formulas to the requirements of other European countries where you are willing to export them
  • Do scientific & regulatory & marketing monitoring which enable to anticipate the withdrawal of products, the safety issues, new interesting scientific studies, the arrival of new players on the market…

 

More information on www.nutraveris.com

Contact our Scientific & Regulatory experts at NUTRAVERIS

contact@nutraveris.com, +33 2 96 76 54 87

Tuesday, March 19, 2019
Category : NEWS, TRAINING | Author : experts | Comment : No Comments
Tags:

Sorry, this entry is only available in French.

NOL, Nutraveris Online, the most efficient data solution to create, keep up-to-date and launch your products in the 28 EU member states, used for 10years by more than 500 industry leaders informs you:

 

Red yeast rice has been suspected to induce some toxicological side effects. The aim of this systematic review and meta-analysis was to examine the available scientific evidences on the safety of red yeast rice supplementations. Data were pooled from 53 randomized and controlled trial, for a total of 8535 subjects (5537 supplemented with red yeast rice and 4303 controls).

Red yeast rice

Results showed that red yeast rice was not associated with increased risk of musculoskeletal disorders (OR = 0.94, 95% CI: 0.53-1.65). In addition, reduced risk of non-skeletal musculoskeletal adverse events (OR = 0.59, 95% CI: 0.50-0.69) and serious adverse events (OR = 0.54, 95% CI: 0.46-0.64) have been measured with red yeast rice in comparison to control. Furthermore, increasing the doses of monacolin K was negatively associated with increasing risk of non-skeletal musculoskeletal adverse events.

 

In conclusion, this large meta-analysis demonstrate that the use of red yeast rice as hypocholesterolemic supplement is not associated with safety concern.

 

 

Fogacci F, Banach M, Mikhailidis DP, Bruckert E, Toth PP, Watts GF, Reiner Ž, Mancini J, Rizzo M, Mitchenko O, Pella D, Fras Z, Sahebkar A, Vrablik M, Cicero AFG; Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group the International Lipid Expert Panel (ILEP). SAFETY OF RED YEAST RICE SUPPLEMENTATION: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS. Pharmacol Res. 2019 Mar 4. pii: S1043-6618(19)30317-2.

 

This information has been sourced by NOL, a collaborative and complete tool which contains all Regulatory, Scientific and Marketing data

  • It solves all regulatory issues since it contains the required information on all ingredients authorized in the 28 European member states…on regulatory status, health claims, authority opinions
  • It protects your investments since it is updated in real time with reliable quality information analyzed and reviewed by our experts, available hotline.
  • It enables you to be the most responsive with monthly reports and live alerts and a personal use of the information with a report editing tool and customizable bookmarks.

With NOL let’s : 

  • Formulate new innovative products
  • Check if your already existing formulas are still compliant with the in force regulations
  • Adapt your existing formulas to the requirements of other European countries where you are willing to export them
  • Do scientific & regulatory & marketing monitoring which enable to anticipate the withdrawal of products, the safety issues, new interesting scientific studies, the arrival of new players on the market…

 

More information on www.nutraveris.com

Contact our Scientific & Regulatory experts at NUTRAVERIS

contact@nutraveris.com, +33 2 96 76 54 87